you, good morning, everyone. Kristin, Thank and
to outstanding our another and We quarter. As execute across to strategic us propel executed strong plans you drove market market on a heard defense Kristin first commercial mention, product to launches, our and ability simultaneously half. expansion
second $XXX XX% Adjusted reported million quarter, we a basis grew the income of XX% $X.X billion growing in on In X% on X% basis posted and net operationally. reported and operationally. revenue, a
pain growth driven $XXX animal Quarterly portfolio. posted OA Globally, innovative our companion was mAb million. by
$XXX of And revenue Simparica million. which million, franchise key posted franchise from our Simparica Trio. million $XXX includes $XXX contributed dermatology Our
also livestock Our growth portfolio $XXX million with strong revenue. in saw
execution, pain. Looking focus OA to on I'd first closely and success at like our
our our franchises, lagging launching our first-in-class know trajectory. strategy, significantly remain we experience continue execute billion-dollar in other As to therapies confident pain than we development market launch Based U.S. OA more on lookalikes. we require that
customers sales our tools reps information the veterinary safety is interactions interactive and top and medical Chief Solensia of reached industry resources This on interactions the vets and In our teams reinforce KOLs. U.S., to These Medical have our through X,XXX have had ensure thousands the Officer individual the and with owners. vet we over on of efficacy of have with sessions visits. Librela pet and technicians and
the positive signs know deploying are are better than anyone, capital from owners detect DTC owners. we we pet therapies them help the to available our of Additionally, based to treatment strategy. know improving lives OA on and these Pet We and pets want their the options. testimonials expand
In now purchasing in The approaching adoption. of see of product. clinics U.S., customer the Librela quickly. penetrated we with are XX%, Reorder positive penetration the are satisfaction. impact leading record reception this of is our and which over in rates indicator reflected XX% market the history product has No the
into have expansion. the moderate untreated, to XX% now what This in more market shipment for share. glimpse expand expect U.S. still cases largely Europe, than is to making is success, continues gain we addressable our and a expanding were continued room Despite In OA market Librela time, mild we and up early as over just of that cases. the total significant
After product. efficacy, than focus XX% a stop decade performance doesn't and more growing safety driver, key of we in a critical a franchise the launch quarter. our Our execution dermatology exceptional is still on after operationally
U.S., vet including across chewable owner indications, is APOQUEL derm multiple needs any franchise, driving increasing, CYTOPOINT. and methods or administration designed of different the APOQUEL, APOQUEL suit their clinic dermatological growth different volume across pet In cover and preference. to and visits The are both CYTOPOINT,
also revenue. Our chronic seasonal derm lifelong providing as which with from cases, total and conditions make as full treatment spectrum majority of for of products pruritic acute up address conditions, the derm dogs relief well a
studies, pet And happy with global their are owners the efficacy. vets extremely and safety results. veterinarians satisfaction In approximately report XX% APOQUEL of with and
grow of we meets the competition. ability face portfolio patients, the vet confident comprehensive of and even their in needs Our are our in and needs to revenue,
the is earlier. for significant opportunities expansion mentioned confidence that fueled market That by Kristin
dog not First, and a atopic an the treatment through either untreated direct-to-consumer helping itchy the million educate in on X pet with dogs we options. vet of targeting are treated signs the prescription that all dermatitis or by U.S. to owners advertising, are
the in are products who U.S., like Additionally, alternative steroids. are million X prescribed there dogs
these customers and through are to in efficacy. safety our confident ability proven We new our win
from trends the are We and doses care, injectable formulations chewable health including compliance. alternative to base therapies, drawing increasing due to channel more growth, same also patient pet reference within
the growth trajectory, long-term franchise provide outstanding markets this are markets early there growth should stages of where key momentum. and many Lastly, highlights dermatology is our maturity. our These in international
has expansion to first half dermatology Our launches a excellence contributed our execution and key year. on pain and of the great
on growth. the let's results. our revenue animal Now segment XX% U.S. growing XX% grew and posting move to in companion with quarter, XX% livestock
our in the companion mAb, franchise. For surpassed U.S. portfolio Simparica Performance quarter. across key pain the was our animal $X our sales OA billion driven first and by dermatology Trio time,
growth and retail reflecting preference was in home for and of driven increased by evolution compliance medications. pet-owner dispensing trends delivery, convenience Portfolio oral largely the on
usage treatment In the shift. channel therapeutic injectable of alternative growing is the clinic, to offset
mAbs, and posted U.S. combined in on increased pain million, in a sales Our Librela $XX generated clinic QX. $XX Solensia, utilization. primarily Librela million
are than adoption our to Thus, any we in mentioned I As our date, trajectory. product history. higher is market in confident
million Solensia revenue. posted in $XX
pleased in We we are continue with the what to seeing OA feline be space.
have trends in ago. nearly X positive we OA feline As which doubled since see almost years our visits, Kristin launch mentioned,
in Simparica growth quarter million on the of XX% Trio revenue. $XXX posted in U.S.
We but leadership to we our continue a on position market, triple year do parasiticide not launch-and-done execute defending Trio, second mentality. not growing with combination the in our are it. we Again, entering and with competition just take
a average not the highlighting posted XX base. the majority stickiness but of only our the in which also competitive We first-mover was XX% growth customer advantage, moving past over our total of market, months,
efficacious vets product. is absence reluctant Lastly, channel, from owners in vet of switch and future the are meaningful of Trio the In differentiation, a with puppies, indicator winning to pet Simparica performance. safe, a leading
were Key increased growth with largest million was quarter, APOQUEL $XXX conversion. sales the in the growing XX%. product for dermatology U.S. chewable benefiting the APOQUEL driver, from
Much solutions, APOQUEL growing injectable and space. CYTOPOINT chronic growth bolstered by to to the evolving ability vet driven Trio landscape. cases. Simparica home continues of win success the be preference for our Earlier, pet demographics been and in Kristin in with and for by shifting to has our pet owner especially alluded retail owner delivery
channels need these for them. we owners, products of convenience popular are are with customers our products self-administered The to committed available where making and increasingly our pet
retail is second. prescription and the come sales channel now best-selling and the the of estimate that is APOQUEL sales of We XX% via products Trio Trio Simparica retail Currently, channel. in X/X APOQUEL over
the rate for for Trio quarter. overall and APOQUEL this these both exceeded alternative channel products rate Additionally, growth growth
to This product-only Growing pet-owner in the indicator preference led not has is an of alternative decline best evolving in given visits grown for performance, volume why consistently landscape. channel our a convenience are clinic we visits. have
portfolio our animal distributor returning channel Our diagnostics growth U.S. following after quarter, grew the X% companion QX downs inventory work change. to strategies in
strong supply primarily on the had XX%, a soft of driven last livestock growing quarter, had comparable period U.S. ceftiofur, from year. which timing a
Moving operationally. to XX%, animal grew livestock foreign on and excluding X% of grew impact reported International and our operationally, on exchange. segment. Revenue the grew X% Companion basis a XX%
and Our pain growth International in companion animal key franchises, dermatology portfolio OA offset driven impacts by by partially China. Simparica, was
operationally $XX was operationally. XX% in grew driven million Our by to quarter. the International Simparica growing XX% franchise Simparica in sales Growth
continue as benefits in markets. in Eastern inflationary increased use Latin see as price We America and to high well Europe
grew from China. Europe, Trio in the DTC million sales, account on positive recent growth operationally key and focus our continued Simparica $XX on XX% launch impact in benefiting of in
key by higher XX% We saw sales. of the operationally most and new $XXX franchise driven double-digit our million in markets, grew compliance Our major patients. growth quarter, dermatology across posting in
Japan Growth was headwinds due preprice partially in offset in buy-ins QX. by to
earlier, opportunity market in markets the international to for significant see for Many As we growth. are early highlighted of development runway stages significant with growth. we continue
OA combined were grew operationally, growing our XX% posting operationally. Internationally, in million, International $XX Librela mAbs sales million XX% revenue. $XX pain
launches significant markets, last international in quarter, last XXXX. QX in As our the we of which occurred have lapped we highlighted
Solensia sales operationally. XX% were million, $XX growing
diagnostics in by China, animal animal grew offset franchise. much companion companion by across International operationally, strong performance expected portfolio driven Our Asia Europe. and was XX% with International revolution of partially declines growth
our volume in driven saw livestock primarily driven poultry We the strong in by portfolio in contributions inflationary strong from and for markets. demand with International in in this increases, by Norway. grew X% and fish quarter, price cattle quarter, operationally vaccines high growth price
Growth in to due was in of well the species in offset a comparable impact our challenging rotations. unfavorable partially fish of most livestock price volume by as other quarter as declines
as what As challenges our and but companion well pressure late in said animal to products headwinds in certain the livestock. as expected, China livestock, putting companion quarters, throughout the moderate with impact swine. have on growth on economic for year, are continued the we especially animal expected the persist, across several Consistent is expected year
is of one successful things Fiscal execution. unlocks the discipline P&L across the that
and of continued we move As we on highlights, reinvesting to some to our the commitment from the wanted our business to see returns confidence investments. in in our we reaffirm those
of basis declined a on points gross Adjusted margins basis. reported XX XX.X%
Foreign impact exchange had basis XXX unfavorable points. of an
markets. especially freight due lower increases, inflationary to we higher FX, margins saw in high costs, price mix offset partially Excluding higher and manufacturing costs, favorable by
net in for XX% Adjusted operationally. operationally of to Adjusted operating grew the adjusted expenses Improvements increased operational diluted contributed and increases which income, XX% to prudent R&D. Contributing expense and EPS quarter. X% operational growth XX% growth was operationally. this in gross margin SG&A operationally growth X% grew
to repurchased high in repurchase $XXX In want I we shares. million a program. our share record quarter, Lastly, the highlight
a we August approval on billion Board to date. repurchase our X, $X received Additionally, we largest new that program, announced share for program
repurchase expected program, at The years, shares approved expected canceled which to $X.X ability to and value to XXXX, multiyear completed over to commitment the up continued be be billion company's in in can of this year. confidence are The our program previous December time. shareholders. return repurchased share X any to period reflects was This is a be
additives planned guidance, our the to portfolio. of moving an feed update divestiture Before on medicated
close this the we some divestiture As Kristin mentioned, half. expecting time in to second are
be sale the and to the may of is not subsequent adjusted reflective guidance current deal. close of the Our
revenue our As $XXX seasonality. portfolio we stated approximately linear this in million announcement, generated XXXX, April in in roughly with
to Now moving guidance full for on year XXXX.
we going particularly that May's performance, dermatology Our growth execution half us our our outstanding July. XXXX to gives business first forward. Simparica late key ability exchange during foreign confidence drive rates earnings franchises, reflects Please and Thus, our our guidance guidance of and call. through provided in raising across note are demonstrated
$X.X and billion, range revenue expect For the billion $X.XX we to a operational of X% year, growth. XX% between
trajectory stated As remains OA track. pain we our on earlier,
year Librela the for expectations remain Our for unchanged.
the net of operational to in We of be income $X.XX to now $X.XX growth XX.X% representing expect XX.X%. billion billion, range adjusted to
revenue our income grow We than our the long commitment advertising. increasing are maintaining to faster activities, over net such term, adjusted while as in demand-generating direct-to-consumer investment
have to operating While optimal the we same leverage saw may subsequent exceptional not -- of quarter, leverage quarters due may the of timing investments. have level this
Finally, be to to reported range and we $X.XX the $X.XX. in $X.XX $X.XX of in EPS the diluted expect of adjusted diluted to range be EPS to
Q&A, In execute as on peers. our closing, portfolio our the vision our strategic diversity ability to before and of relationships go well us outperform as to continually strength our and our we allows to
portfolio benchmark the in utmost continue We to moving colleagues have our to and confidence the best-in-class set forward.
for the things to Now to hand over the I'll open your Operator? operator questions. line
